Shift Workers, Jet Lag, and Circadian Sleep Disruption: A Clinical Guide

Shift work sleep disorder, jet lag, and menopause- or age-related circadian flattening are related but distinct problems. Shift work sleep disorder (SWSD) is a diagnosed circadian-rhythm sleep-wake disorder requiring at least three months of insomnia or excessive sleepiness tied directly to a non-standard schedule, per the American Academy of Sleep Medicine's International Classification of Sleep Disorders, 3rd edition (ICSD-3). Jet lag is a self-limited, schedule-transition problem, not a chronic diagnosis. Aging, pregnancy, and menopause each shift the underlying sleep physiology in ways that make circadian disruption from any cause harder to tolerate and slower to resolve. Medications discussed below include FDA-approved drugs used on-label (modafinil, armodafinil, low-dose doxepin, suvorexant, lemborexant, fezolinetant), off-label uses (zolpidem for jet lag, orexin antagonists for SWSD), and melatonin, which in the United States is sold as an unregulated dietary supplement rather than an approved drug.

The useful clinical question is not "does melatonin or light therapy work for circadian problems" in the abstract. It is which direction a given person's clock needs to move, how much biological buffer they have (age, pregnancy, comorbid sleep apnea, cardiometabolic risk), and whether the underlying driver is a schedule that can be changed or one that cannot. Two people with identical jet lag symptoms but opposite travel directions need opposite light and melatonin timing; using the wrong direction can lengthen recovery instead of shortening it.

What shift work sleep disorder is, and who is affected

The circadian pacemaker sits in the suprachiasmatic nucleus (SCN) of the anterior hypothalamus and runs on a period close to but not exactly 24 hours, entrained daily by light signals reaching it through the retinohypothalamic tract. When a work schedule forces wakefulness during the body's biological night, the SCN keeps signaling for sleep during work hours and for wakefulness during the scheduled sleep period, producing the characteristic SWSD symptoms: difficulty staying alert on shift, difficulty falling or staying asleep afterward, and mood or cognitive changes.

Estimates of how many shift workers meet full SWSD diagnostic criteria vary widely across studies and industries, reflecting different definitions and sampling. A precise population prevalence figure should not be treated as settled without checking the specific study's definition and population; readers should treat any single percentage quoted online, including in earlier versions of this article, as needing verification against the primary paper before being repeated as fact.

Long-term shift work has been associated with elevated cardiovascular and metabolic risk in large observational cohorts, and separately, IARC has placed night-shift work involving circadian disruption in a probable-carcinogen category based on a combination of animal and limited human epidemiological evidence. These are real signals worth discussing with a clinician, particularly for workers with additional cardiometabolic risk factors, but they are observational associations, not proof of a fixed, quantifiable increase in individual risk, and exact relative-risk or odds-ratio figures circulating for these associations should be verified against the specific paper before being quoted as precise numbers.

How circadian disruption differs by population

Older adults

Sleep architecture changes with age independent of schedule: sleep tends to become lighter and more fragmented, and melatonin secretion amplitude declines. Because of this, older shift workers and older travelers generally need more days to re-entrain after a schedule change or a multi-time-zone flight than younger adults do. The exact number of extra days per time zone varies by individual and should not be quoted as a fixed rule.

The 2023 American Geriatrics Society Beers Criteria advises against first-generation antihistamines such as diphenhydramine for adults over 65 because of anticholinergic risks including confusion and urinary retention. CBT-I and, where medication is warranted, low-dose doxepin (FDA-approved specifically for sleep maintenance insomnia at low doses) or an orexin receptor antagonist are generally preferred over sedating antihistamines or benzodiazepines in this age group. This is general geriatric prescribing guidance, not individualized dosing advice; any medication decision for a specific older adult should go through their own clinician, who can weigh fall risk, polypharmacy, and comorbidities.

Pregnancy

Pregnancy fragments sleep on its own, through nocturia, fetal movement, reflux, and hormonal changes in upper-airway tone. Layering shift work on top of that raises measurable concern for obstetric risk. Multiple observational studies and at least one systematic review have linked shift work, particularly rotating schedules, to higher rates of preterm birth compared with fixed daytime schedules. The exact magnitude of that association (odds ratio, confidence interval) varies by study and should be verified against the specific paper before being cited as a precise number to a patient.

Melatonin crosses the placenta, and human safety data in pregnancy remain limited. Current general obstetric guidance does not support routine melatonin supplementation in pregnancy outside of research settings; pregnant patients should discuss any sleep aid, including over-the-counter options, with their obstetric clinician before use (see the American College of Obstetricians and Gynecologists for patient-facing guidance). CBT-I, delivered in person or digitally, avoids this uncertainty and is a reasonable first-line option in pregnancy. Obstructive sleep apnea is underdiagnosed in pregnancy and should be considered in anyone reporting loud snoring or witnessed apneas, particularly shift workers whose sleep is already fragmented, because untreated moderate-to-severe OSA in pregnancy carries its own risks that deserve separate clinical evaluation.

Postmenopausal women

The menopause transition affects sleep through at least two mechanisms: declining estradiol and progesterone reduce slow-wave sleep depth, and vasomotor symptoms (hot flashes and night sweats) cause brief arousals that fragment sleep even when the person does not fully wake or recall waking. Insomnia symptoms are reported more frequently after menopause than before it in comparative studies, though the exact percentage difference varies by study population and should not be repeated as a fixed statistic without checking the source.

Menopausal hormone therapy can improve sleep, largely by reducing vasomotor symptoms rather than through direct sedation; some data suggest micronized progesterone specifically may add a mild sedative effect through its neurosteroid metabolite. Fezolinetant (Veozah), a non-hormonal neurokinin-3 receptor antagonist, is FDA-approved for moderate-to-severe vasomotor symptoms of menopause and may secondarily improve sleep by reducing hot flashes, though it is not itself an approved sleep medication. Whether hormone therapy or fezolinetant is appropriate for a given patient depends on personal and family history (clotting risk, hormone-sensitive cancer history, cardiovascular risk) and should be decided with her own clinician, not from a general guide. For postmenopausal women whose insomnia does not resolve with sleep hygiene alone, CBT-I is the guideline-preferred first step before medication escalation.

Jet lag: which direction, and what actually shortens it

Jet lag comes from crossing time zones faster than the internal clock can follow. As a general rule described in the circadian literature, the clock adjusts faster to phase delays (associated with westward travel, staying up later) than to phase advances (associated with eastward travel, going to bed earlier), which is the commonly cited reason eastward travel tends to feel worse. Exact rates of adjustment per day vary across studies and individuals and should be treated as approximate, not as a fixed formula for any one traveler.

Getting the direction wrong is the most common practical mistake. Eastward travel calls for morning light exposure at the destination and melatonin timed to the new, earlier bedtime; westward travel calls for evening light exposure and melatonin timed to the new, later bedtime. Light exposure at the wrong time of day can shift the clock in the wrong direction and lengthen recovery rather than shorten it.

Melatonin taken near the target destination bedtime is a long-studied jet-lag strategy in the sleep literature, generally described as more about reducing subjective jet-lag severity and helping sleep onset at the new local time than about eliminating jet lag outright. In the United States, melatonin is sold as a dietary supplement, not an FDA-approved drug, so dose, purity, and labeling are not regulated the way a prescription medication's would be; readers should not assume a specific milligram dose is validated by regulatory review. Caffeine can mask jet-lag-related sleepiness and support alertness during the day but does not itself speed up circadian re-entrainment, so relying on caffeine alone tends to delay rather than solve the underlying problem. Short-term prescription options such as armodafinil or modafinil for daytime alertness, or zolpidem for a night or two at the destination bedtime, are used off-label for jet lag in some clinical settings; none of these re-entrains the clock, and zolpidem in particular carries next-day sedation risk that is more pronounced in adults over 65.

The core, quotable takeaway: jet lag recovery time depends on travel direction and the number of time zones crossed, phase-advance adjustment (eastward travel) is generally slower than phase-delay adjustment (westward travel), and correctly timed light exposure plus melatonin near the destination bedtime are the interventions with the most consistent support in the sleep-medicine literature for shortening recovery, while caffeine and short-term hypnotics manage symptoms without correcting the underlying misalignment. Exact day-counts and percentage improvements attributed to any single intervention vary across studies and should be verified against the primary trial before being quoted as a fixed number to a patient.

Treating shift work sleep disorder: a layered approach

Clinical guidance generally treats SWSD management as layered rather than as a single fix: schedule optimization first, behavioral and light strategies second, medication third if functional impairment continues.

Schedule. Where the employer allows it, forward-rotating schedules (day to evening to night) are generally considered easier on the circadian system than backward-rotating schedules, because they align with the body's natural tendency toward phase delay. Not every workplace can offer this, and the decision is often outside an individual worker's control.

Light and darkness. Bright light (commonly described as around 10,000 lux) at the start of the wake period can help shift the clock later over about a week of consistent use, which suits night-shift workers trying to stay alert through the night; blocking morning light on the commute home (blue-light-blocking glasses, sunglasses, blackout curtains at home) helps prevent the body from prematurely re-entraining to daytime.

CBT-I. Cognitive behavioral therapy for insomnia is the guideline-preferred first-line treatment for chronic insomnia symptoms in adults generally, including insomnia connected to shift work, and its components (stimulus control, sleep restriction, relaxation training) do not carry medication risk. It requires a structured multi-week course rather than a single-session fix, which is a real access barrier for some shift workers.

Medication for sleepiness. Modafinil is FDA-approved specifically for excessive sleepiness associated with shift work disorder; armodafinil carries a similar approved indication. These reduce sleepiness during the shift; they are not treatments for the insomnia that can occur after the shift ends, and they do not correct the underlying circadian misalignment.

Medication for insomnia after the shift. When daytime sleep after a night shift remains inadequate despite behavioral measures, orexin receptor antagonists such as suvorexant or lemborexant are approved for chronic insomnia disorder generally and are used off-label for SWSD-related insomnia; they are generally considered to carry less next-day impairment risk than older sedative-hypnotics at standard doses, though individual response varies and this is a decision for the prescribing clinician, not a self-directed choice.

What is established, what is plausible, and what is not established

Established: SWSD is a recognized ICSD-3 diagnosis with defined criteria; CBT-I is a guideline-preferred first-line insomnia treatment; modafinil and armodafinil carry FDA-approved indications for SWSD-related sleepiness; low-dose doxepin is FDA-approved for sleep-maintenance insomnia; fezolinetant is FDA-approved for menopausal vasomotor symptoms; light timing relative to travel direction (morning light for eastward travel, evening light for westward travel) is a widely accepted circadian principle.

Plausible but not settled to a precise number: the exact percentage of shift workers who meet full SWSD criteria; the precise magnitude of cardiovascular, metabolic, or cancer risk increase attributable to night-shift work specifically (versus confounding lifestyle and socioeconomic factors); the exact odds-ratio increase in preterm birth from shift work in pregnancy; the exact minutes of sleep improvement from a specific hormone therapy regimen in menopause. These associations appear repeatedly in the literature but the specific numbers require verification against the primary paper before being used in patient counseling.

Not established from the material available here: any individualized melatonin dose, timing, or duration for a specific reader; any claim that melatonin, light therapy, or a specific medication eliminates jet lag or SWSD symptoms rather than reducing them; and any claim that a supplement product sold in the US has been FDA-reviewed for safety or dosing in the way a prescription drug has.

When to seek care rather than self-manage

Anyone with loud snoring, witnessed pauses in breathing, or excessive daytime sleepiness despite adequate opportunity to sleep should be evaluated for obstructive sleep apnea rather than assuming shift work or jet lag explains the symptoms. Pregnant patients with these symptoms should be evaluated promptly given the added obstetric stakes. Chest pain, new shortness of breath, or signs of a cardiac event in a night-shift worker warrant emergency care, not a sleep-hygiene adjustment. Insomnia lasting more than three months despite consistent sleep hygiene and, where relevant, appropriate light and schedule strategies, warrants a formal CBT-I referral and a discussion with a clinician about whether a sleep study is needed to rule out apnea, periodic limb movement disorder, or REM sleep behavior disorder, the last two of which increase in prevalence with age and after menopause.

Circadian direction and risk-tier decision guide

This is a structured way to think through what actually changes management, not a substitute for individualized clinical advice.

Step 1: Identify the direction problem.

Step 2: Identify the risk tier before choosing an intervention.

• Healthy adult under 65, not pregnant, no known sleep apnea: behavioral and light strategies first; melatonin or short-term medication as adjuncts if needed, per a clinician's guidance.
• Adult over 65: avoid diphenhydramine and other first-generation antihistamines; be cautious with zolpidem due to next-day sedation and fall risk; favor CBT-I and, if medication is needed, low-dose doxepin or an orexin antagonist chosen by a clinician.
• Pregnant: avoid routine melatonin use outside clinical guidance; screen for OSA if snoring or witnessed apneas are reported; prioritize CBT-I and obstetric-guided management.
• Postmenopausal with vasomotor symptoms: consider whether hot flashes, not circadian misalignment alone, are driving the insomnia; discuss hormone therapy or fezolinetant with a clinician if vasomotor symptoms are prominent, and use CBT-I as first-line for the insomnia itself.
• Anyone with suspected sleep apnea, cardiovascular symptoms, or insomnia beyond three months: escalate to formal evaluation rather than continuing self-management.

Step 3: Reassess, don't assume a fixed protocol works forever. Shift schedules change, pregnancies progress, and menopausal symptoms evolve over years, so a strategy that worked six months ago may need revisiting rather than repeating by default.